Literature DB >> 21070610

Structural determinants of PERK inhibitor potency and selectivity.

Hong Wang1, Jaime Blais, David Ron, Timothy Cardozo.   

Abstract

The unfolded protein response (UPR) is a coordinated program that promotes cell survival under conditions of endoplasmic reticulum stress and is required in tumor progression as well. To date, no specific small molecule inhibitor targeting this pathway has been identified. Pancreatic endoplasmic reticulum kinase (PERK), one of the UPR transducers, is an eIF2α kinase. Compromising PERK function inhibits tumor growth in mice, suggesting that PERK may be a cancer drug target, but identifying a specific inhibitor of any kinase is challenging. The goal of this study was to identify some pair-wise receptor-ligand atomic contacts that confer selective PERK inhibition. Compounds selectively inhibiting PERK-mediated phosphorylation in vitro were identified using an initial virtual library screen, followed by structure-activity hypothesis testing. The most potent PERK selective inhibitors utilize three specific kinase active site contacts that, when absent from chemically similar compounds, abrogates the inhibition: (i) a strong van der Waals contact with PERK residue Met7, (ii) interactions with the N-terminal portion of the activation loop, and (iii) groups providing electrostatic complementarity to Asp144. Interestingly, the activation loop contact is required for PERK selectivity to emerge. Understanding these structure-activity relationships may accelerate rational PERK inhibitor design.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21070610      PMCID: PMC3058854          DOI: 10.1111/j.1747-0285.2010.01048.x

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  48 in total

1.  TOMOCOMD-CARDD, a novel approach for computer-aided 'rational' drug design: I. Theoretical and experimental assessment of a promising method for computational screening and in silico design of new anthelmintic compounds.

Authors:  Yovani Marrero-Ponce; Juan A Castillo-Garit; Ervelio Olazabal; Hector S Serrano; Alcidez Morales; Nilo Castañedo; Froylán Ibarra-Velarde; Alma Huesca-Guillen; Elisa Jorge; Arletys del Valle; Francisco Torrens; Eduardo A Castro
Journal:  J Comput Aided Mol Des       Date:  2004-10       Impact factor: 3.686

Review 2.  PKR and eIF2alpha: integration of kinase dimerization, activation, and substrate docking.

Authors:  Susan S Taylor; Nina M Haste; Gourisankar Ghosh
Journal:  Cell       Date:  2005-09-23       Impact factor: 41.582

3.  Druggability of SCF ubiquitin ligase-protein interfaces.

Authors:  Timothy Cardozo; Ruben Abagyan
Journal:  Methods Enzymol       Date:  2005       Impact factor: 1.600

Review 4.  From acute ER stress to physiological roles of the Unfolded Protein Response.

Authors:  J Wu; R J Kaufman
Journal:  Cell Death Differ       Date:  2006-03       Impact factor: 15.828

5.  Structural basis for autoinhibition and mutational activation of eukaryotic initiation factor 2alpha protein kinase GCN2.

Authors:  Anil K Padyana; Hongfang Qiu; Antonina Roll-Mecak; Alan G Hinnebusch; Stephen K Burley
Journal:  J Biol Chem       Date:  2005-06-17       Impact factor: 5.157

6.  In silico identification of novel EGFR inhibitors with antiproliferative activity against cancer cells.

Authors:  Claudio N Cavasotto; María A Ortiz; Ruben A Abagyan; F Javier Piedrafita
Journal:  Bioorg Med Chem Lett       Date:  2006-01-18       Impact factor: 2.823

Review 7.  Strategies toward the design of novel and selective protein tyrosine kinase inhibitors.

Authors:  P Traxler; P Furet
Journal:  Pharmacol Ther       Date:  1999 May-Jun       Impact factor: 12.310

8.  ER stress-regulated translation increases tolerance to extreme hypoxia and promotes tumor growth.

Authors:  Meixia Bi; Christine Naczki; Marianne Koritzinsky; Diane Fels; Jaime Blais; Nianping Hu; Heather Harding; Isabelle Novoa; Mahesh Varia; James Raleigh; Donalyn Scheuner; Randal J Kaufman; John Bell; David Ron; Bradly G Wouters; Constantinos Koumenis
Journal:  EMBO J       Date:  2005-09-08       Impact factor: 11.598

9.  Identification and characterization of pancreatic eukaryotic initiation factor 2 alpha-subunit kinase, PEK, involved in translational control.

Authors:  Y Shi; K M Vattem; R Sood; J An; J Liang; L Stramm; R C Wek
Journal:  Mol Cell Biol       Date:  1998-12       Impact factor: 4.272

10.  Activation-dependent substrate recruitment by the eukaryotic translation initiation factor 2 kinase PERK.

Authors:  Stefan J Marciniak; Lidia Garcia-Bonilla; Junjie Hu; Heather P Harding; David Ron
Journal:  J Cell Biol       Date:  2006-01-16       Impact factor: 10.539

View more
  17 in total

Review 1.  Unfolded Protein Response as a Therapeutic Target in Cardiovascular Disease.

Authors:  Guangyu Zhang; Xiaoding Wang; Thomas G Gillette; Yingfeng Deng; Zhao V Wang
Journal:  Curr Top Med Chem       Date:  2019       Impact factor: 3.295

Review 2.  Small molecule strategies to harness the unfolded protein response: where do we go from here?

Authors:  Julia M D Grandjean; R Luke Wiseman
Journal:  J Biol Chem       Date:  2020-09-04       Impact factor: 5.157

Review 3.  Therapeutic Opportunities in Eukaryotic Translation.

Authors:  Jennifer Chu; Jerry Pelletier
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

Review 4.  Molecular pathways: the PERKs and pitfalls of targeting the unfolded protein response in cancer.

Authors:  Nancy L Maas; J Alan Diehl
Journal:  Clin Cancer Res       Date:  2014-09-02       Impact factor: 12.531

Review 5.  The Integrated Stress Response and Phosphorylated Eukaryotic Initiation Factor 2α in Neurodegeneration.

Authors:  Sarah Bond; Claudia Lopez-Lloreda; Patrick J Gannon; Cagla Akay-Espinoza; Kelly L Jordan-Sciutto
Journal:  J Neuropathol Exp Neurol       Date:  2020-02-01       Impact factor: 3.685

Review 6.  Bioinformatics and variability in drug response: a protein structural perspective.

Authors:  Jennifer L Lahti; Grace W Tang; Emidio Capriotti; Tianyun Liu; Russ B Altman
Journal:  J R Soc Interface       Date:  2012-05-02       Impact factor: 4.118

7.  Specific small molecule inhibitors of Skp2-mediated p27 degradation.

Authors:  Lily Wu; Arsen V Grigoryan; Yunfeng Li; Bing Hao; Michele Pagano; Timothy J Cardozo
Journal:  Chem Biol       Date:  2012-12-21

8.  Dual activators of protein kinase R (PKR) and protein kinase R-like kinase PERK identify common and divergent catalytic targets.

Authors:  Huijun Bai; Ting Chen; Jie Ming; Hong Sun; Peng Cao; Dahlene N Fusco; Raymond T Chung; Michael Chorev; Qi Jin; Bertal H Aktas
Journal:  Chembiochem       Date:  2013-06-19       Impact factor: 3.164

Review 9.  Trends in kinase drug discovery: targets, indications and inhibitor design.

Authors:  Misty M Attwood; Doriano Fabbro; Aleksandr V Sokolov; Stefan Knapp; Helgi B Schiöth
Journal:  Nat Rev Drug Discov       Date:  2021-08-05       Impact factor: 84.694

10.  Can the energy gap in the protein-ligand binding energy landscape be used as a descriptor in virtual ligand screening?

Authors:  Arsen V Grigoryan; Hong Wang; Timothy J Cardozo
Journal:  PLoS One       Date:  2012-10-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.